1. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
- Author
-
Harry J. de Koning, Ivica Grgurević, Patrick S. Kamath, Laurent Castera, Emmanuel Tsochatzis, Frank Lammert, Isabel Graupera, Ann T. Ma, Núria Fabrellas, Dominique Roulot, Pere Ginès, Mª Alba Diaz, Salvador Augustin, Andrea Martini, Vincent Wai-Sun Wong, Judit Pich, Rosa Maria Morillas, Philip N. Newsome, Miquel Serra-Burriel, Maja Thiele, Aleksander Krag, Phillipp Hartmann, Robert J. de Knegt, Michael P Manns, Montserrat García-Retortillo, Jörn M. Schattenberg, Indra Neil Guha, Alina M. Allen, Llorenç Caballería, Institut Català de la Salut, [Ginès P, Graupera I] Liver Unit, Hospital Clínic of Barcelona, Barcelona, Spain. August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain. Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain. Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. [Castera L] Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France. Université de Paris, Paris, France. Inserm UMR 1149, Centre de Recherche Sur L'inflammation, Paris, France. [Lammert F] Department of Medicine II, Saarland University Medical Center, Homburg, Germany. Institute for Occupational Medicine and Public Health, Saarland University, Homburg, Germany. Health Sciences, Hannover Medical School, Hannover, Germany. [Serra-Burriel M] Epidemiology, Statistics, and Prevention Institute, University of Zurich, Zurich, Switzerland. [Allen AM] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. [Salvador A] Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain. Unitat Hepàtica, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Cirrosi hepàtica - Diagnòstic ,Cirrhosis ,Fibrosi ,Biopsy ,enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES] ,Population ,Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES] ,Otros calificadores::/diagnóstico [Otros calificadores] ,Disease ,Fetge -- Malalties ,Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Asymptomatic ,Gastroenterology ,Global Burden of Disease ,Liver disease ,Hepatitis B, Chronic ,SDG 3 - Good Health and Well-being ,Liver Function Tests ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Fibrosis ,Internal medicine ,Prevalence ,Cribatge (Medicina) ,Other subheadings::/diagnosis [Other subheadings] ,diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Humans ,Mass Screening ,Medicine ,education ,liver fibrosis ,education.field_of_study ,Hepatology ,business.industry ,Fatty liver ,Cirrosi ,Hepatitis C, Chronic ,medicine.disease ,Early Diagnosis ,Liver ,Disease Progression ,Elasticity Imaging Techniques ,medicine.symptom ,Transient elastography ,business - Abstract
Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%-in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression. LiverScreen Consortium and the European Commission under the H20/20 program (847989); AGAUR (2017SGR-01281); Centro de Investigacion Biomedica en Enfermedades Hepaticas y Digestivas; Fundación de Investigación Sanitaria, cofunded by Instituto Carlos III–Subdirección General de Evaluación and the European Regional Development Fund (PI18/01330, PI18/00662, and PI18/00862); and Gilead’s Investigator–sponsored research program (IN-ES-989-5309)
- Published
- 2021
- Full Text
- View/download PDF